Automating Infectious Disease Specialty Drug Prior Auth

The Criticality of Infectious Disease Specialty Drug Prior Auth

Infectious disease prior authorization frequently involves high-cost antivirals for conditions like HCV and HIV, complex antifungal regimens, and outpatient parenteral antibiotic therapy (OPAT). These therapies are often time-sensitive, making efficient prior authorization crucial for timely patient access and optimal clinical outcomes. Delays can lead to treatment interruptions or progression of disease, underscoring the need for streamlined PA processes.

Navigating Benefit and Site-of-Care Complexities for ID Therapies

Many specialty drugs used in infectious disease, such as certain antivirals or infused antifungals, can fall under either the medical or pharmacy benefit depending on the payer, plan, and administration route. Incorrect benefit determination leads to submission rejections and delays. Furthermore, medical-benefit ID drugs, particularly for OPAT, are subject to payer site-of-care policies, which may steer away from expensive hospital outpatient settings towards infusion centers or home infusion.

Common Prior Authorization Triggers in Infectious Disease

• High-cost antivirals (e.g., for HCV, HIV) requiring specific diagnostic and treatment history.
• Complex antifungal agents for systemic infections, often with step-therapy requirements.
• Outpatient Parenteral Antibiotic Therapy (OPAT) for prolonged IV antibiotic courses, frequently tied to site-of-care policies.
• Novel or biosimilar biologics used in specific ID-related inflammatory conditions.
• Regimens requiring extensive prior-line therapy documentation for approval.

Klivira's Automated Approach to ID Specialty Drug PAs

Klivira's platform provides automated benefit-side determination for infectious disease specialty drugs, directing submissions to the correct channel—whether via NCPDP SCRIPT ePA for pharmacy benefits or X12 278 and Da Vinci PAS where available for medical benefits. This intelligent routing prevents common misclassification errors that delay access to critical ID therapies.

Streamlining Clinical Documentation and Fulfillment for ID Drugs

Our system integrates with EMRs to extract and compile necessary clinical documentation, including medication history and treatment response data from FHIR MedicationRequest and Observation resources, critical for demonstrating step-therapy compliance for complex HIV regimens or antifungals. Post-approval, Klivira coordinates the handoff to specialty pharmacies, minimizing fulfillment delays for patient-administered ID drugs.

Addressing Key Failure Modes in ID Prior Authorization

Klivira specifically addresses common failure points in infectious disease specialty drug prior authorization. This includes automated identification of payer site-of-care policy requirements for infused ID drugs, surfacing these before submission to prevent denials. Our platform also flags potential issues with manufacturer copay assistance for Medicare patients, a critical consideration for high-cost ID therapies, for discussion with your compliance team.